Compare Abeona Therapeutics Inc (ABEO) vs Alcon AG (ALC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Alcon AG — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Alcon AG trades at $72.42 (market cap $36.44B). The key difference: Alcon AG is far larger — about 86.5× Abeona Therapeutics Inc's market cap, and Alcon AG pays a 0.48% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ALC | |
|---|---|---|
Market Cap | $421.19M | $36.44B |
Sector | Health | Health |
52-Week High | $7.45 | $90.12 |
52-Week Low | $4.17 | $62.02 |
Enterprise Value | $276.10M | $40.28B |
Dividend Yield | — | 0.48% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →
